[ad_1]
These data are critical for protecting immunocompromised patients from symptomatic Covid-19
file photo
Abu Dhabi has launched a Real World Evidence (RWE) study to provide insights into the safety and efficacy of AstraZeneca’s long-acting antibody combination Evusheld in protecting immunocompromised patients in the UAE from symptomatic Covid-19 infection Key real-world data.
The study is one of many outcomes of a partnership declaration signed last year by the Abu Dhabi Department of Health (DoH) and AstraZeneca.
The collaboration aims to further enhance health science research and development and foster innovation in healthcare as part of DoH’s strategy to increase patient access to quality healthcare.
The EVOLVE real-world evidence study, expected to run until the end of 2023, with up to 1,000 participants, is a collaboration between AstraZeneca and Sheikh Khalifa Medical City (SKMC) Hospital in Abu Dhabi under the supervision of DoH .
Abu Dhabi is one of the first cities in the world to receive the first batch of AstraZeneca’s long-acting antibody drug, Evusheld, to ensure continuity of world-class care in the country.
This multi-country prospective observational study will support at-risk populations in the United Arab Emirates and the wider Middle East and Africa region by building on the body of evidence on how Evusheld protects against the Covid-19 virus.
Dr Jamal Mohammed Al Kaabi, Deputy Minister of Health (DoH), Abu Dhabi, said: “We are delighted to see the results of our joint work with partners around the world to position Abu Dhabi as a leading destination for healthcare and life sciences Innovation incubator.
With its advanced infrastructure, the UAE is able to attract global partnerships with established leaders in the health and pharmaceutical sectors, as well as those who choose Abu Dhabi as a key destination for innovative research projects. “
Al Kaabi stressed that the health and safety of the Abu Dhabi community and the world remains the top priority of the Ministry of Health, which ensures that the latest innovations in treatment and prevention are available to all individuals with different needs and health conditions.
About 2% of the global population has a compromised immune system. They either didn’t respond to the Covid-19 vaccine, or they didn’t respond enough. These include people with cancer or certain immune diseases, people on dialysis, people who have received immunosuppressive therapy, and others with suppressed immune systems.
Dr Nawal Al Kaabi, Chief Medical Officer at SKMC and Head of Research at EVOLVE, said: “The risk of Covid-19 infection is far from over, especially for the immunocompromised and vulnerable. Real-world evidence is essential to help us better understand the virus The evolution of the technology and the establishment of additional tools to protect high-risk populations are critical.
Beyond the pandemic, this innovative research will advance regional efforts to improve the quality of healthcare, advance the digitization of medical data, and meet the growing demand for locally-derived clinical data that captures our unique demographics. “
AstraZeneca GCC and Pakistan Medical Director Eva Turgonyi commented: “As Covid-19 continues to cast a shadow around the world, it is important to continue to protect the health and safety of all members of the community, especially the most vulnerable. Easier Complications from Covid-19.
Unfortunately, there is a group of patients where vaccination does not provide adequate protection. By collecting real-world data from the United Arab Emirates, we can better understand how AstraZeneca’s long-acting antibody combination, Evusheld, protects immunocompromised patients and enables them to return to their daily lives. “
Evusheld has been shown to significantly protect against symptomatic Covid-19 compared to placebo, according to data from the PROVENT Phase III Pre-Exposure Prophylaxis Trial. It also retains neutralizing activity against Omicron and all other variants of interest to date.
Third, Evusheld has been shown to significantly reduce the risk of severe Covid-19 or death compared to placebo in non-hospitalized patients with mild to moderately symptomatic infections.
Evusheld is currently under Emergency Use Authorization in the United Arab Emirates, Kingdom of Saudi Arabia, Bahrain, Qatar and Egypt, and is the only antibody therapy to receive Emergency Use Authorization in the United States for COVID-19 PrEP.
Abu Dhabi has come up with a pioneering model in its response to the Covid-19 pandemic. The emirate has been recognised in global rankings for its efficiency in tackling the pandemic and ensuring the health and safety of community members, placing it at the top of the world’s cities. These efforts now run parallel to the continuum of economic growth in the emirate.
Also read:
[ad_2]
Source link